Literature DB >> 8707951

Monocyte activation in patients with non-seminomatous germ cell tumour of the testis before and after tumour eradication.

A Trulson1, S Nilsson, P Venge.   

Abstract

AIMS: To investigate the kinetics of normalisation of monocyte oxidative activity following tumour eradication.
METHODS: Whole blood lucigenin enhanced chemiluminescence was studied in patients with non-seminomatous germ cell tumours. Group 1 comprised 14 patients who had been "cured" of their cancer (the term "cured" as used in this report denotes a relapse free period of at least three years). Group 2 comprised 15 patients who were followed from diagnosis to up to two years after the start of treatment.
RESULTS: Lucigenin enhanced chemiluminescence of whole blood in the "cured" patients was similar to that of controls and lower than that in patients who had not yet received chemotherapy (group 2). After treatment, chemiluminescence decreased slowly and did not normalise until 18 months after the start of treatment. Tumour necrosis factor alpha (TNF alpha) concentrations were normal in "cured" patients but were raised in those who had not yet received treatment. TNF alpha was normalised 12 months after start of treatment. Alpha-fetoprotein concentrations were raised in most patients but normalised rapidly after tumour eradication.
CONCLUSIONS: The activity of blood monocytes, as measured by whole blood lucigenin enhanced chemiluminescence, is increased in cancer. This activity may be a consequence of the presence of tumour cells. Immunocompetent cells remain active for over a year after eradication of the tumour.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8707951      PMCID: PMC500476          DOI: 10.1136/jcp.49.5.381

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  33 in total

Review 1.  The biology of the monocyte system.

Authors:  H W Ziegler-Heitbrock
Journal:  Eur J Cell Biol       Date:  1989-06       Impact factor: 4.492

Review 2.  Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self.

Authors:  I J Fidler; A J Schroit
Journal:  Biochim Biophys Acta       Date:  1988-11-15

Review 3.  Oxygen radicals, inflammation, and tissue injury.

Authors:  P A Ward; J S Warren; K J Johnson
Journal:  Free Radic Biol Med       Date:  1988       Impact factor: 7.376

4.  Human monocytes selectively bind to cells expressing the tumorigenic phenotype.

Authors:  H Shimizu; D Wyatt; R D Knowles; C D Bucana; E J Stanbridge; E S Kleinerman
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 5.  Secretory products of macrophages.

Authors:  C F Nathan
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

Review 6.  The biology of cachectin/TNF--a primary mediator of the host response.

Authors:  B Beutler; A Cerami
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

7.  Increased production of tumor necrosis factor and prostaglandin E2 by monocytes in cancer patients and its unique modulation by their plasma.

Authors:  K Nara; H Odagiri; M Fujii; Y Yamanaka; M Yokoyama; T Morita; M Sasaki; M Kon; T Abo
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

8.  Lucigenin-enhanced chemiluminescence in blood is increased in cancer.

Authors:  A Trulson; S Nilsson; P Venge
Journal:  Am J Clin Pathol       Date:  1989-04       Impact factor: 2.493

9.  An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4.

Authors:  F Pericle; M Giovarelli; M P Colombo; G Ferrari; P Musiani; A Modesti; F Cavallo; F Di Pierro; F Novelli; G Forni
Journal:  J Immunol       Date:  1994-12-15       Impact factor: 5.422

10.  Evidence for tumour necrosis factor/cachectin production in cancer.

Authors:  F Balkwill; R Osborne; F Burke; S Naylor; D Talbot; H Durbin; J Tavernier; W Fiers
Journal:  Lancet       Date:  1987-11-28       Impact factor: 79.321

View more
  1 in total

1.  Effect of intraperitoneally administered recombinant murine granulocyte-macrophage colony-stimulating factor (rmGM-CSF) on the cytotoxic potential of murine peritoneal cells.

Authors:  A H Klimp; J Regts; G L Scherphof; E G de Vries; T Daemen
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.